Notice NOT-GM-25-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-25-008 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) aims to support new biomedical, behavioral, and social science investigators who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies, secondary analysis of existing data, small, self-contained research projects, development of research methodology, and development of new research technology. Applicants are encouraged to conduct projects that ultimately have the potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address one or more High-Priority Research Topic(s) related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this NOFO will be administered by NIH using funds made available through FDA CTP and the FSPTCA. Research results from this NOFO are expected to generate findings and data directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Notice NOT-DE-26-002 from the NIH Guide for Grants and Contracts

Notice NOT-HL-25-028 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-437 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access limited identifiable data or biospecimens from the ECHO Cohort to study high-priority areas of maternal and child health.

Notice NOT-OD-25-127 from the NIH Guide for Grants and Contracts

Notice NOT-ES-25-005 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-215 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-125 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-383 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.

Funding Opportunity PAR-25-442 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.

Notice NOT-OD-25-126 from the NIH Guide for Grants and Contracts

Notice NOT-TR-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-26-003 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for a National Alzheimer's Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) field as: 1) A national data resource, collecting data from the Alzheimer's Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) A facilitator of current and future AD/ADRD research; and 3) The central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.

Funding Opportunity PAR-25-333 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase.

Funding Opportunity RFA-AR-25-014 from the NIH Guide for Grants and Contracts. Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UH3 Clinical Trial Required)

Funding Opportunity RFA-AR-25-013 from the NIH Guide for Grants and Contracts. Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-RM-25-003 from the NIH Guide for Grants and Contracts. The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.

Funding Opportunity RFA-AG-26-001 from the NIH Guide for Grants and Contracts. Add Health is a nationally representative, longitudinal cohort study of individuals primarily born from 1976 through 1982 who were first interviewed as adolescents in grades 7-12 (ages 12-19) in 1994-1995. Add Health respondents are now at midlife, offering a uniquely valuable timepoint to assess risk and resilience for Alzheimers disease and related dementias (AD/ADRD). This NOFO will continue core study aspects including the mixed-mode survey, in-home health visit, venous blood collection, and data dissemination activities while further developing Add Health as a population-representative data resource to understand life course factors shaping inequities in outcomes related to aging and AD/ADRD.

Notice NOT-EB-25-007 from the NIH Guide for Grants and Contracts